LIQUID BANDAGE CONTAINING PEPTIDE ANTI-INFLAMMATORY ACTIVE INGREDIENTS AND PREPARATION METHOD THEREOF

Abstract

The present invention provides a liquid bandage containing peptide anti-inflammatory active ingredient and a preparation method thereof, which relates to the technical field of medical materials. The liquid bandage comprises film-forming agents; one or more plasticizers, comprising glycerin; one or more anti-inflammatory substances, comprising oligopeptide with an amino acid sequence of Leu-Leu-Phe-Thr-Thr-Gln; and solvent, comprising deionized water. The liquid bandage can promote the expression of interleukin 10 (IL-10) and inhibit the expressions of interleukin 6 (IL-6) and tumor necrosis factor (TNF-α). Peptide anti-inflammatory active ingredient can produce good anti-inflammatory activity. Further, the liquid bandage can enhance the close contact between gel and the injured skin surface, increase the cleanliness of the wound surface, and can increase a clearance rate of inflammatory cells.

Claims

1, A liquid bandage containing peptide anti-inflammatory active ingredient, comprising: one or more film-forming agents; one or more plasticizers, comprising glycerin; one or more anti-inflammatory substances, comprising oligopeptide with an amino acid sequence of Leu-Leu-Phe-Thr-Thr-Gln (SEQ ID NO.1); and solvent, comprising deionized water.

2, The liquid bandage according to claim 1, wherein the film-forming agents comprising: polyvinyl alcohol, and modified chitosan.

3, The liquid bandage according to claim 2, wherein the modified chitosan being hydroxycinnamic acid modified chitosan, and dihydroxycoumarin grafted on the hydroxycinnamic acid modified chitosan.

4, The liquid bandage according to claim 3, wherein a specific method for modifying chitosan by hydroxycinnamic acid comprising: 1) adding dimethyl sulfoxide into chitosan, stirring, then slowly dropping alkaline solution, and alkalinizing for 1.8-2.2 h by stirring; 2) dissolving hydroxycinnamic acid in dimethyl sulfoxide, slowly dropping into solution prepared in step 1) while stirring continuously during dropping; then reacting at 58-62° C. for 5.5-6 h; performing suction filtration after cooling, fully washing with deionized water, absolute ethanol and acetone in sequence, and drying to obtain hydroxycinnamic acid modified chitosan.

5, The liquid bandage according to claim 1, wherein the liquid bandage is prepared by a solution blending method.

6, A method for preparing the liquid bandage according to claim 1, wherein steps and conditions for preparing liquid bandages as follows: based on weight, liquid bandages comprising 50-70 parts of film-forming agent, 1-1.2 parts of oligopeptide, 80-90 parts of plasticizer, and 150-200 parts of solvent; dissolving the film-forming agent in the solvent, stirring until completely dissolved, adding oligopeptide, adding plasticizer, and stirring evenly to obtain the liquid bandage.

7, The method according to claim 6, wherein the oligopeptide is a natural oligopeptide.

8, The method according to claim 7, wherein a raw material for preparing the natural oligopeptide is tuna scraps.

9, The method according to claim 8, wherein methods of preparing the natural oligopeptide comprising: using double enzymes to hydrolyze tuna protein step by step: at the first step, hydrolase being pepsin, and at the second step, hydrolase being flavor protease; removing aromatic amino acid; isolating and purifying.

10, The method according to claim 9, wherein the aromatic amino acid is removed by using activated carbon.

Description

DESCRIPTION OF THE DRAWINGS

[0035] FIG. 1 is a gel-forming temperature and a water absorption rate of a liquid bandage in test example 1 of the present invention;

[0036] FIG. 2 is an aggregation of neutrophils in a skin wound according to test example 2 of the present invention;

[0037] FIG. 3 is the number of aggregated neutrophils on a 0.09 mm.sup.2 wound surface according to test example 2 of the present invention;

[0038] FIG. 4 is an immunoblot of IL-10, IL-6, and TNF-α according to test example 2 of the present invention;

[0039] FIG. 5 is relative expression levels of IL-10, IL-6, and TNF-α according to test example 2 of the present invention;

[0040] FIG. 6 is a healing rate of wound surface after liquid bandage treatment in test example 2 of the present invention.

DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

[0041] It should be noted that the following detailed description is exemplary and intended to provide further explanation of the invention. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by skilled in the art to which this invention belongs.

[0042] It should be noted that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to limit the embodiments according to the disclosure. As used herein, the singular forms are intended to include the plural forms as well, unless the context clearly indicates otherwise.

[0043] In order to enable those skilled in the art to understand the technical solutions of the disclosure more clearly, the disclosure will be described in further detail below in conjunction with the embodiments.

Example 1

[0044] A method for preparing a liquid bandage containing peptide anti-inflammatory active ingredient included the following steps.

[0045] Double enzymes were used to hydrolyze tuna protein step by step: taking minced tuna, where the enzyme for hydrolysis of the first step was pepsin, the enzyme amount added was 600 U/g with pH 2.0; the ratio of feed and water being 1:7, the temperature being 35° C., and the hydrolysis time being 3 h; In the second step, the enzyme for hydrolysis being flavor protease, and the enzyme amount added being 50,000 U/g, with pH 6.5, the temperature being 50° C., and the hydrolysis time being 4 h, and thus obtaining protein hydrolysate;

[0046] removal of aromatic amino acid: filtering the protein hydrolysate under vacuum, adding 200 mesh activated carbon powder at a ratio of solid to liquid of 1:20 with pH 3.0, the temperature being 35° C. and time being 3 h; aromatic amino acid being static adsorption; after adsorption, centrifuging at 4000 rpm for 10 min, and taking supernatant to obtain an oligopeptide solution;

[0047] gel filtration: concentrating the oligopeptide solution after static dearomatization with activated carbon, lyophilizing, then taking 50 mg for dissolution in 1.5 mL distilled water, and separating and purifying with Sephadex G-25 dextran gel chromatography column (1.6×50 cm); after loading sample, eluting with pH 7.2 phosphate buffer, collecting one tube of eluent every 230 seconds with each tube being 3 mL, and measuring the ultraviolet absorbance (A) of each tube at 220 nm and 280 nm to obtain four components A1, A2, A3, A4, respectively detecting the amino acid composition and content of each component, and calculating the F value of each component according to the following formula:

F=(Val+Ile+Leu)/(Tyr+Phe);

[0048] in the above formula, Val, Ile, Tyr, Phe, Leu respectively represent the amounts of valine, isoleucine, tyrosine, phenylalanine, and leucine in the unit of mg/mL.

[0049] Calculations show that the F value of A3 was the highest, i.e. 37.52.

[0050] Purification of oligopeptide by reverse high-performance liquid chromatography: concentrating the A3 component oligopeptide solution after gel separation and lyophilizing; taking 1 mg to be dissolved to 1 mL with ultrapure water containing 0.05% TFA, centrifuging, taking supernatant, and loading RP-HPLC chromatography; chromatographic conditions: injection volume 500 μL, flow rate 0.8 mL/min, detection wavelength 280 nm, column temperature 25° C., mobile phase being phase A-B, where the phase A was ultrapure water containing 0.05% trifluoroacetic acid, and the phase B was acetonitrile containing 0.05% trifluoroacetic acid; gradient elution conditions (phase B): 0-9 min, 0% B; 9-40 min, 0%-100% B; 40-50 min, 100% B. Finally, collecting four components M1, M2, M3, and M4 on a chromatographic peak, lyophilizing, weighing, determining the amino acid sequence of the collected components, and accurately determining the molecular weight of each component, obtaining the M3 component as a target oligopeptide with an amino acid sequence Leu-Leu-Phe-Thr-Thr-Gln and a molecular weight of 721.58 Da;

[0051] preparation of modified chitosan: adding 1.5 g of chitosan into a three-necked flask, adding 10 mL of dimethyl sulfoxide, stirring and swelling at 30° C. for 1 h, slowly dropwise adding alkaline solution, and alkalinizing for 2 h by stirring; taking 3 g of hydroxycinnamic acid to be dissolved in dimethyl sulfoxide, slowly dropping into the flask, while stirring continuously during the dropping addition, then reacting at 60° C. for 5.8 h, after that, cooling, suction filtrating, fully washing with deionized water, absolute ethanol and acetone in sequence, and drying to obtain hydroxycinnamic acid modified chitosan;

[0052] dissolving 1 g of hydroxycinnamic acid-modified chitosan in 100 mL of 2% acetic acid solution, swelling for 2 h, adding into the alkaline solution for precipitation while stirring, suction filtering, washing with acetone, suction-filtering to half-dry, transferring to 100 mL of acetone, stirring into a suspension, dropping 5 mL of epichlorohydrin therein, and adjusting the temperature to 35° C. and reacting for 24 h; then adding 3 mL of dihydroxycoumarin, reacting at 60° C. for 6 h, and then adding 8 mL of dihydroxycoumarin, 50 mL NaOH solution, 0.05 g potassium iodide, stirring for 4 h, cooling, and suction filtering, and then washing by deionized water, absolute ethanol and acetone thoroughly and drying to obtain dihydroxycoumarin grafted modified chitosan;

[0053] preparation of the liquid bandage: dissolving 16 g of polyvinyl alcohol in 160 g of deionized water, stirring at 90° C. in a water bath until completely dissolved, adding 40 g of modified chitosan, after complete dissolution, adding 1 g of high F value oligopeptide and 64 g of glycerin; after uniformLy mixing, preparing the liquid bandage.

Comparative Example 1

[0054] The high F value oligopeptide was not added to the liquid bandage, and the rest was completely the same as in Example 1.

Comparative Example 2

[0055] Chitosan was not modified with hydroxycinnamic acid, and the rest was exactly the same as in Example 1.

Comparative Example 3

[0056] Chitosan was not grafted with dihydroxycoumarin, and the rest was exactly the same as in Example 1.

Comparative Example 4

[0057] Chitosan was not modified with hydroxycinnamic acid, nor grafted with dihydroxycoumarin, and the rest was completely the same as in Example 1.

Comparative Example 5

[0058] Chitosan was not modified with hydroxycinnamic acid, nor grafted with dihydroxycoumarin, no high F value oligopeptide was added to the liquid bandage, and the rest was completely the same as in Example 1.

Test Example 1

[0059] Detection of Temperature Sensitivity of Liquid Bandage.

[0060] The prepared liquid bandage was placed in a water bath environment and gradually heated at a rate of 0.5° C./min. After each temperature increase, the solution system was observed. If the system was inverted with no liquid flowing out, the temperature was the lowest gel forming temperature.

[0061] Detection of Water Absorption Rate of Liquid Bandage:

[0062] The prepared liquid bandage was gelled in a water bath, and the film was placed in a PBS solution and swelled and balanced at room temperature. After drying and weighing the wet film, the formula for calculating the water absorption rate of the gel was as follows:

Water absorption rate=(W−W.sub.0)/W.sub.0×100%;

[0063] In the above formula, W is a mass of wet gel at the time of swelling balancing; W.sub.0 is a mass of dry gel. FIG. 1 shows a gel forming temperature and a water absorption rate of liquid bandage.

[0064] It can be seen from FIG. 1 that the gel forming temperatures of Example 1 and Comparative Example 1 are about 36.5° C., which is within a body temperature range of the human body. The gel forming temperatures of Comparative Example 2, Comparative Example 3, Comparative Example 4, and Comparative Example 5 are higher than the human body temperature; and the water absorption rates of Example 1 and Comparative Example 1 are significantly higher, which shows that chitosan modified with hydroxycinnamic acid, or grafted by dihydroxycoumarin can improve the water absorption of the liquid bandage, so as to maintain the gel forming temperature at about 36.5° C.

Test Example 2

[0065] Building of a mouse skin resection wound model: intraperitoneally injecting 100 μL of 2% pentobarbital sodium, removing mouse hair, culturing in a dry and clean environment for 24 h, and making a total skin resection wound with a diameter of 8 mm on both sides of the back of the mouse respectively by using a puncher. The wounds for which no treatment is performed were taken as a control group.

[0066] The treated mice were cultured in a dry and clean environment, photographs were taken after the second day of culture, and wound tissues (including normal tissues about 5 mm away from the wound surface) were extracted for subsequent experiments.

[0067] Wound Surface Neutrophil Detection:

[0068] The skin tissue was embedded and sliced, and a rabbit neutrophil elastase (NE) immunohistochemical detection kit was used to detect the aggregation of neutrophils. The aggregation of neutrophils in a skin wound surface was shown at a scale of 25 μm in FIG. 2. The aggregation number of neutrophils on a wound surface of 0.09 mm.sup.2 was shown in FIG. 3.

[0069] It can be seen from FIG. 3 that the aggregation numbers of neutrophils in the wound surface of 0.09 mm.sup.2 in Example 1 and Comparative Example 1 are significantly higher than those in Comparative Example 2, Comparative Example 3, Comparative Example 4, and Comparative Example 5, which shows that hydroxycinnamic acid modified chitosan, dihydroxycoumarin grafted chitosan are able to enhance the close contact between the gel and the injured skin surface, increase the cleanliness of the wound surface, increase the clearance rate of inflammatory cells, and reduce the inflammation of the wound surface. The aggregation numbers of neutrophils on the wound surface of 0.09 mm.sup.2 in the Comparative Example 2, Comparative Example 3 and Comparative Example 4 were significantly higher than that of Comparative Example 5, which shows that the liquid bandage containing the high F value oligopeptide with an amino acid sequence Leu-Leu-Phe-Thr-Thr-Gln and a molecular weight of 721.58 Da can reduce the occurrence of inflammation, which was attested by the aggregation of neutrophils in the skin wound as shown in FIG. 2.

[0070] The expressions of interleukin 10 (IL-10), interleukin 6 (IL-6) and tumor necrosis factor (TNF-α) were detected by immunoblotting:

[0071] using β-actin as a reference protein, and detecting the expressions of IL-10, IL-6 and TNF-α by WB immunoblotting kit.

[0072] FIG. 4 shows the immunoblots of IL-10, IL-6 and TNF-α, and FIG. 5 shows the relative expression levels of IL-10, IL-6 and TNF-α.

[0073] It can be seen from FIG. 4 and FIG. 5 that the relative expression levels of IL-10 in Example 1, Comparative Example 2, Comparative Example 3, and Comparative Example 4 are significantly higher than those in Comparative Example 1 and Comparative Example 5, and the relative expressions level of IL-6 and TNF-α are significantly lower than those of Comparative Example 1 and Comparative Example 5. It is indicated that the liquid bandage containing the high F value oligopeptide with the amino acid sequence Leu-Leu-Phe-Thr-Thr-Gln and the molecular weight of 721.58 Da is able to promote the expression of interleukin 10 (IL-10) and inhibit the expressions of the proinflammatory cytokine interleukin 6 (IL-6) and tumor necrosis factor (TNF-α) so as to reduce the occurrence of inflammation.

[0074] Detection of Wound Surface Healing Process:

[0075] On the 1st, 4th, 7th, and 14th days after treatment, the wound surface healing after treating the total resection wound with the liquid bandage was observed. The wound healing rate is shown in FIG. 6

[0076] It can be seen from FIG. 6 that the healing rate of Example 1 is significantly higher than those of Comparative Example 1, Comparative Example 2, and Comparative Example 3, and the healing rate of Comparative Example 4 is significantly higher than that of Comparative Example 5, which shows that the liquid bandage containing the high F value oligopeptide can reduce the occurrence of inflammation and promote the healing of wound surface. The healing rate of Example 1 is significantly higher than those of Comparative Example 2, Comparative Example 3 and Comparative Example 4, and the healing rate of Comparative Example 1 is significantly higher than that of Comparative Example 5, which shows that chitosan modified with hydroxycinnamic acid or grafted with dihydroxycoumarin can reduce the inflammatory response of the wound surface, improve the curative effect and accelerate wound healing

[0077] The conventional approach in the above embodiments is the prior art known to those skilled in the art, and thus will not be described in detail here.

[0078] The above embodiments are only used to illustrate the present invention, rather than limit the present invention. Those of ordinary skill in the art can make various changes and modifications without departing from the spirit and scope of the present invention. Therefore, all equivalent technical solutions also belong to the scope of the present invention, and the protection scope of the present invention should be defined by the claims